TrademarkDir
NEUROVANCE
DEAD

Serial Number

77864680

Owner

NEUROVANCE, INC.

Attorney

Dana B. Robinson

First Use Date

Oct 18, 2012

Filing Date

Nov 4, 2009

Add to watchlist:

No watchlists yet
+ Create New Watchlist
View on USPTO

NEUROVANCE Trademark

Serial Number: 77864680 • Registration: 4276086

NEUROVANCE is a trademark filed by NEUROVANCE, INC. on November 4, 2009. The trademark is classified under Class 42 (Computer & Scientific). The application is currently no longer active.

Owner Contact Info

NEUROVANCE, INC. (4 trademarks)

43 Thorndike Street, Suite S1-3
Cambridge, MA 02141

Entity Type: 03

Euthymics Bioscience, Inc. (2 trademarks)

43 Thorndike Street, Suite S1-3
Cambridge, MA 02141

Entity Type: 03

Trademark Details

Filing Date

November 4, 2009

Registration Date

January 15, 2013

First Use Anywhere

October 18, 2012

First Use in Commerce

October 18, 2012

Published for Opposition

April 6, 2010

Cancellation Date

August 16, 2019

Goods & Services

Laboratory research in the field of treatment and or prophylaxis of disorders of the central nervous system; Pharmaceutical research and development; Pharmaceutical research services; Research and development of technology in the field of drug discovery, pharmaceuticals, all related to the treatment of disorders of the central nervous system

Filing History

CANCELLED SEC. 8 (6-YR)
Aug 16, 2019 C8..
COURTESY REMINDER - SEC. 8 (6-YR) E-MAILED
Jan 15, 2018 REM1
AUTOMATIC UPDATE OF ASSIGNMENT OF OWNERSHIP
May 10, 2017 ASGN
REGISTERED-PRINCIPAL REGISTER
Jan 15, 2013 R.PR
NOTICE OF ACCEPTANCE OF STATEMENT OF USE E-MAILED
Dec 11, 2012 SUNA
LAW OFFICE REGISTRATION REVIEW COMPLETED
Dec 10, 2012 REGV
ALLOWED PRINCIPAL REGISTER - SOU ACCEPTED
Dec 10, 2012 CNPR
STATEMENT OF USE PROCESSING COMPLETE
Dec 3, 2012 SUPC
USE AMENDMENT FILED
Nov 29, 2012 IUAF
TEAS STATEMENT OF USE RECEIVED
Nov 29, 2012 EISU
NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
May 12, 2012 EXRA
SOU EXTENSION 4 GRANTED
May 11, 2012 EX4G
SOU EXTENSION 4 FILED
May 6, 2012 EXT4
SOU TEAS EXTENSION RECEIVED
May 6, 2012 EEXT
NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Dec 1, 2011 EXRA
SOU EXTENSION 3 GRANTED
Nov 30, 2011 EX3G
SOU EXTENSION 3 FILED
Nov 25, 2011 EXT3
SOU TEAS EXTENSION RECEIVED
Nov 25, 2011 EEXT
NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
May 10, 2011 EXRA
SOU EXTENSION 2 GRANTED
May 9, 2011 EX2G
SOU EXTENSION 2 FILED
May 5, 2011 EXT2
SOU TEAS EXTENSION RECEIVED
May 5, 2011 EEXT
NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Dec 1, 2010 EXRA
SOU EXTENSION 1 GRANTED
Nov 30, 2010 EX1G
CASE ASSIGNED TO INTENT TO USE PARALEGAL
Nov 29, 2010 AITU
SOU EXTENSION 1 FILED
Nov 15, 2010 EXT1
SOU TEAS EXTENSION RECEIVED
Nov 15, 2010 EEXT
APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED
Nov 12, 2010 CHAN
TEAS CHANGE OF OWNER ADDRESS RECEIVED
Nov 12, 2010 COAR
NOA MAILED - SOU REQUIRED FROM APPLICANT
Jun 1, 2010 NOAM
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Apr 6, 2010 NPUB
PUBLISHED FOR OPPOSITION
Apr 6, 2010 PUBO
LAW OFFICE PUBLICATION REVIEW COMPLETED
Mar 4, 2010 PREV
ASSIGNED TO LIE
Mar 4, 2010 ALIE
APPROVED FOR PUB - PRINCIPAL REGISTER
Feb 9, 2010 CNSA
ASSIGNED TO EXAMINER
Feb 9, 2010 DOCK
NOTICE OF PSEUDO MARK MAILED
Nov 13, 2009 MPMK
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Nov 12, 2009 NWOS
NEW APPLICATION ENTERED
Nov 7, 2009 NWAP

Related Trademarks

More from this Owner

RIGHT RATIO FOR THE RIGHT PATIENT

RIGHT RATIO FOR THE RIGHT PATIENT

RIGHT RATIO FOR THE RIGHT PATIENT

RIGHT RATIO FOR THE RIGHT PATIENT

CENTANAFADINE SR IS A NOREPINEPHRINE- AND DOPAMINE-PREFERRING TRIPLE REUPTAKE INHIBITOR THAT HAS THE RIGHT RATIO FOR THE RIGHT PATIENT

CENTANAFADINE SR IS A NOREPINEPHRINE- AND DOPAMINE-PREFERRING TRIPLE REUPTAKE INHIBITOR THAT HAS THE RIGHT RATIO FOR THE RIGHT PATIENT

CENTANAFADINE SR IS A NOREPINEPHRINE- AND DOPAMINE-PREFERRING TRIPLE REUPTAKE INHIBITOR THAT HAS THE RIGHT RATIO FOR THE RIGHT PATIENT

CENTANAFADINE SR IS A NOREPINEPHRINE- AND DOPAMINE-PREFERRING TRIPLE REUPTAKE INHIBITOR THAT HAS THE RIGHT RATIO FOR THE RIGHT PATIENT

ZIMPHANI

ZIMPHANI

CENTANAFADINE SR IS A NOREPINEPHRINE- AND DOPAMINE-PREFERRING TRIPLE REUPTAKE INHIBITOR THAT HAS THE RIGHT RATIO FOR THE RIGHT PATIENT

CENTANAFADINE SR IS A NOREPINEPHRINE- AND DOPAMINE-PREFERRING TRIPLE REUPTAKE INHIBITOR THAT HAS THE RIGHT RATIO FOR THE RIGHT PATIENT